Open to opportunities

Gauri Deoras

@gaurideoras

Message

I evaluate life sciences assets, regulatory pathways, and deep-tech investment opportunities.

Netherlands

Message

What I'm looking for

I'm looking to apply my life sciences, regulatory, commercial diligence, and investment experience to evaluating high-impact healthcare or deep-tech opportunities and supporting informed strategic decisions.

I've led commercial diligence and valuation of clinical-stage oncology assets across 40+ countries through GD Consulting & Coaching, combining rNPV modelling, regulatory pathway analysis, and market insights. I also advise institutional investors including GLG and Guidepoint on regulatory risk and asset positioning.

As a Visiting Associate/Fellow with Deep Tech Capital Partners, Monozukuri Ventures, and Legendary VC, I've screened 500+ companies across robotics, mobility, and climate tech, developed investment memoranda, and supported early-stage deal evaluation across EU, UK, and U.S. markets.

My background spans regulatory strategy and portfolio management at Sandoz, the European Medicines Agency, Alfasigma, Deloitte, Thomson Reuters, and global health consulting engagements. I've managed regulatory submissions across EU, UK, Switzerland, and 40+ global markets while supporting clinical research, drug safety, and portfolio decision-making.

Experience

Work history, roles, and key accomplishments

Current

Visiting Associate/Fellow

Current

Venture Capital

Jan 2024 - Present (2 years 7 months)

Screened 500+ companies across deep-tech sectors and advanced select opportunities to partner review, including one presented to Investment Committee. Developed investment memoranda and supported deal evaluation, including participation in an early-stage SPV investment across EU, UK, and U.S. markets.

Deal Evaluation Deep Tech Robotics Mobility Climate Tech SPV Investments

Current

Founder / Life Sciences Consultant

Current

GD Consulting & Coaching

Jan 2023 - Present (3 years 7 months)

Led commercial diligence and valuation of clinical-stage oncology assets across 40+ countries, integrating rNPV modelling, EU/UK/US regulatory pathway analysis and market insights. Conducted feasibility assessment for a digital technology joint-venture and advised institutional investors on regulatory risk and asset positioning.

RNPV Modeling Regulatory Pathways Market Insights Feasibility Assessment Oncology

Management Consultant

Deloitte

Jan 2022 - Dec 2022 (11 months)

Structured and developed 8+ RFP proposals, supporting engagement scoping, commercial positioning and team configuration in regulated sectors.

RFP Scoping

Portfolio Management

European Medicines Agency

Nov 2021 - Dec 2022 (1 year 1 month)

Assessed clinical data anonymisation strategies for disclosure risk (incl. COVID-19 products) prior to publication. Developed risk-based portfolio prioritisation framework aligned to innovation and public health impact.

Risk Assessment Covid 19

Registration Manager

Sandoz

Jan 2019 - Dec 2021 (2 years 11 months)

Led implementation of regulatory strategy across EU/UK/CH markets, reducing submission volumes by 50% (1.5 versus 3 years). Managed multiple concurrent regulatory submissions by coordinating cross-functional teams across medical, CMC and commercial functions.

Regulatory Strategy Cross functional Coordination CMC Medical Commercial

Regulatory and Pharmacovigilance Specialist

Alfasigma

Jan 2017 - Dec 2019 (2 years 11 months)

Managed new filings and pharmacovigilance activities across 40+ global markets. Assessed product classification (medicinal vs food), ingredient compliance, and claims strategy.

Pharmacovigilance Regulatory Filings Product Classification Product Compliance Claims Strategy Global Markets

Consultant

WHO/EDCTP/IBos Solutions

Jan 2016 - Dec 2017 (1 year 11 months)

Generated cost and policy insights to support investment in drug safety systems in LMICs. Contributed to partnership development and funding coordination for clinical research programs.

Drug Safety Systems Partnership Development Clinical Research

Analytics and Global Client Delivery

Thomson Reuters

Jan 2011 - Dec 2013 (2 years 11 months)

Led Clinical Cost Metrics program, analysing trial cost structures across top 25 pharmaceutical companies. Delivered insights on trial efficiency, cost optimisation and portfolio performance across global portfolios.

Portfolio Performance Pharmaceutical

Education

Degrees, certifications, and relevant coursework

Utrecht University

Master of Science, Drug Innovation

2014 - 2016

Pursued an MSc in Drug Innovation with a minor in Drug Regulatory Science and attended WHO summer schools on pharmacoeconomics and drug policy analysis.